Format

Send to

Choose Destination
Int J Impot Res. 2016 May;28(3):81-7. doi: 10.1038/ijir.2016.3. Epub 2016 Feb 18.

Mesenchymal stem cell-based gene therapy for erectile dysfunction.

Author information

1
Department of Urology, Soonchunhyang University Hospital, College of Medicine, Soonchunhyang University, Seoul, Korea.
2
Biomedical Research Institute, Chung-Ang School of Medicine, Seoul, Korea.

Abstract

Despite the overwhelming success of PDE5 inhibitor (PDE5I), the demand for novel pharmacotherapeutic and surgical options for ED continues to rise owing to the increased proportion of elderly individuals in the population, in addition to the growing percentage of ED patients who do not respond to PDE5I. Surgical treatment of ED is associated with many complications, thus warranting the need for nonsurgical therapies. Moreover, none of the above-mentioned treatments essentially corrects, cures or prevents ED. Although gene therapy is a promising option, many challenges and obstacles such as local inflammatory response and random transgene expression, in addition to other safety issues, limit its use at the clinical level. The use of stem cell therapy alone also has many shortcomings. To overcome these inadequacies, many scientists and clinicians are investigating new gene and stem cell therapies.

PMID:
26888355
DOI:
10.1038/ijir.2016.3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center